ORGO Earnings

ORGO reported its FY2025Q3 earnings on 2025-11-06, showcasing a revenue of 151.00M against an estimate of 134.00M, resulting in a 12.5% surprise. The EPS was 0.18, surpassing the expected 0.07 by 157.14% . The stock experienced a 44.73% price change on the earnings day and a 66.58% change over the next five days, reflecting market reactions to the results.

Following ORGO's FY2025Q3 earnings announcement on 2025-11-06, the stock price moved by 44.73% on the day of the release. Over the subsequent five days, it saw a 66.58% change. Historically, ORGO's stock price tends to shift by an average of +8.18% in the 10 days leading up to earnings and +6.42% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate ORGO’s annual revenue to reach 173.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.17% and EPS estimates Revise Upward by 0.38% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between ORGO's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 0.17%, while EPS estimates moved Revise Upward by 0.38% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ORGO's stock price typically moves by +8.18% in the 10 days before its earnings and +6.42% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 173.00M.

The earnings call presents a mixed picture: strong revenue growth and improved net income are positive, but increased operating expenses and cash position decline are concerning. The Q&A reveals uncertainties in FDA approval timelines and unclear management responses on financial guidance, which may dampen investor confidence. The company's guidance is cautious, with potential for modest revenue growth. Overall, the sentiment is balanced, leading to a neutral prediction for stock movement.